Vital Signs - Getting Through to Oncologists: What Cancer Diagnostic Companies Do to Reach Their Key Customer Group

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on February 21, 2011, provides a strategic insight on how cancer diagnostic companies can reach out to their customer base. Additionally, a company spotlight is provided for BioMarker Strategies, a novel tissue-based cancer diagnostics company that is developing the SnapPathTM ex vivo biomarker platform to improve the treatment of cancer. Reimbursement and regulatory news from the FDA is also provided for week of January 31, 2011.

Table of Contents

Vital Signs - Getting Through to Oncologists: What Cancer Diagnostic Companies Do to Reach Their Key Customer Group Vital Signs: 21 Feb 2011This week's issue




Related Research

Release Date : 26-Sep-17

Region : North America

Release Date : 25-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 08-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.